2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines ========================================================================================================================================================================================================================================== * Rick A. Nishimura * Catherine M. Otto * Robert O. Bonow * Blase A. Carabello * John P. Erwin III * Lee A. Fleisher * Hani Jneid * Michael J. Mack * Christopher J. McLeod * Patrick T. O’Gara * Vera H. Rigolin * Thoralf M. Sundt III * Annemarie Thompson * AHA Scientific Statements * anticoagulation therapy * aortic stenosis * cardiac surgery * heart valves * mitral regurgitation * prosthetic valves * transcatheter aortic valve replacement * tricuspid stenosis * valvular heart disease ## Table of Contents * Preamblee 1160 * 1. Introduction e1161 * 1.1. Methodology and Evidence Review e1162 * 1.2. Organization of the Writing Group e1162 * 1.3. Document Review and Approval e1163 * 2. General Principles e1163 * 2.4. Basic Principles of Medical Therapy e1163 * 2.4.2. Infective Endocarditis Prophylaxis: Recommendation e1163 * 2.4.3. Anticoagulation for Atrial Fibrillation in Patients With VHD: Recommendations (New Section) e1164 * 3. Aortic Stenosis e1164 * 3.2. Aortic Stenosis e1164 * 3.2.4. Choice of Intervention: Recommendations e1164 * 7. Mitral Regurgitation e1167 * 7.2. Stages of Chronic MR e1167 * 7.3. Chronic Primary MR e1168 * 7.3.3. Intervention: Recommendations e1168 * 7.4. Chronic Secondary MR e1170 * 7.4.3. Intervention: Recommendations e1170 * 11. Prosthetic Valves e1171 * 11.1. Evaluation and Selection of Prosthetic Valves e1171 * 11.1.2. Intervention: Recommendations e1171 * 11.2. Antithrombotic Therapy for Prosthetic Valves e1172 * 11.2.1. Diagnosis and Follow-Up e1172 * 11.2.2. Medical Therapy: Recommendations e1173 * 11.3. Bridging Therapy for Prosthetic Valves e1174 * 11.3.1. Diagnosis and Follow-Up e1174 * 11.3.2. Medical Therapy: Recommendations e1174 * 11.6. Acute Mechanical Prosthetic Valve Thrombosis e1175 * 11.6.1. Diagnosis and Follow-Up: Recommendation e1175 * 11.6.3. Intervention: Recommendation e1176 * 11.7. Prosthetic Valve Stenosis e1176 * 11.7.3. Intervention: Recommendation e1177 * 11.8. Prosthetic Valve Regurgitation e1178 * 11.8.3. Intervention: Recommendations e1178 * 12. Infective Endocarditis e1179 * 12.2. Infective Endocarditis e1179 * 12.2.3. Intervention: Recommendations e1179 * Referencese 1181 * Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e1189 * Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) e1191 * Appendix 3. Abbreviations e1195 ## Preamble Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor the development and publication of guidelines without commercial support, and members of each organization volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA. ### Intended Use Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a global impact. Although guidelines may be used to inform regulatory or payer decisions, their intent is to improve patients’ quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment. ### Clinical Implementation Guideline recommended management is effective only when followed by healthcare providers and patients. Adherence to recommendations can be enhanced by shared decision making between healthcare providers and patients, with patient engagement in selecting interventions based on individual values, preferences, and associated conditions and comorbidities. ## Methodology and Modernization The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations including the Institute of Medicine1,2 and on the basis of internal reevaluation. Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information at the point of care to healthcare professionals. Given time constraints of busy healthcare providers and the need to limit text, the current guideline format delineates that each recommendation be supported by limited text (ideally, <250 words) and hyperlinks to supportive evidence summary tables. Ongoing efforts to further limit text are underway. Recognizing the importance of cost–value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology.3 To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual4 and other methodology articles.5–8 ### Selection of Writing Committee Members The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers. ### Relationships With Industry and Other Entities The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found [online](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1). Appendix 1 of the current document lists writing committee members’ relevant RWI. For the purposes of full transparency, writing committee members’ comprehensive disclosure information is available [online](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1), as is comprehensive [disclosure information](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1) for the Task Force. ### Evidence Review and Evidence Review Committees When developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.4–7 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited. An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed of utmost clinical importance that merit formal systematic review. This systematic review will strive to determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review, b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number of patients, and d) the likelihood that the findings can be translated into actionable recommendations. ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians. When a formal systematic review has been commissioned, the recommendations developed by the writing committee on the basis of the systematic review are marked with “sr”. ### Guideline-Directed Management and Therapy The term *guideline-directed management and therapy* (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions. The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States. ### Class of Recommendation and Level of Evidence The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1).4–6 View this table: [Table 1.](http://circ.ahajournals.org/content/135/25/e1159/T1) Table 1. ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015) *Glenn N. Levine, MD, FACC, FAHA* *Chair, ACC/AHA Task Force on Clinical Practice Guidelines* ## 1. Introduction The focus of the “2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease”9,10 (2014 VHD guideline) was the diagnosis and management of adult patients with valvular heart disease (VHD). The field of VHD is rapidly progressing, with new knowledge of the natural history of patients with valve disease, advances in diagnostic imaging, and improvements in catheter-based and surgical interventions. Several randomized controlled trials (RCTs) have been published since the 2014 VHD guideline, particularly with regard to the outcomes of interventions. Major areas of change include indications for transcatheter aortic valve replacement (TAVR), surgical management of the patient with primary and secondary mitral regurgitation (MR), and management of patients with valve prostheses. All recommendations (new, modified, and unchanged) for each clinical section are included to provide a comprehensive assessment. The text explains new and modified recommendations, whereas recommendations from the previous guideline that have been deleted or superseded no longer appear. Please consult the full-text version of the 2014 VHD guideline10 for text and evidence tables supporting the unchanged recommendations and for clinical areas not addressed in this focused update. Individual recommendations in this focused update will be incorporated into the full-text guideline in the future. Recommendations from the prior guideline that remain current have been included for completeness but the LOE reflects the COR/LOE system used when initially developed. New and modified recommendations in this focused update reflect the latest COR/LOE system, in which LOE B and C are subcategorized for greater specificity.4–7 The section numbers correspond to the full-text guideline sections. ### 1.1. Methodology and Evidence Review To identify key data that might influence guideline recommendations, the Task Force and members of the 2014 VHD guideline writing committee reviewed clinical trials that were presented at the annual scientific meetings of the ACC, AHA, European Society of Cardiology, and other groups and that were published in peer-reviewed format from October 2013 through November 2016. The evidence is summarized in tables in the [Online Data Supplement](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC2). ### 1.2. Organization of the Writing Group For this focused update, representative members of the 2014 VHD writing committee were invited to participate, and they were joined by additional invited members to form a new writing group, referred to as the 2017 focused update writing group. Members were required to disclose all RWI relevant to the data under consideration. The group was composed of experts representing cardiovascular medicine, cardiovascular imaging, interventional cardiology, electrophysiology, cardiac surgery, and cardiac anesthesiology. The writing group included representatives from the ACC, AHA, American Association for Thoracic Surgery (AATS), American Society of Echocardiography (ASE), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Cardiovascular Anesthesiologists (SCA), and Society of Thoracic Surgeons (STS). ### 1.3. Document Review and Approval The focused update was reviewed by 2 official reviewers each nominated by the ACC and AHA; 1 reviewer each from the AATS, ASE, SCAI, SCA, and STS; and 40 content reviewers. Reviewers’ RWI information is published in this document (Appendix 2). This document was approved for publication by the governing bodies of the ACC and the AHA and was endorsed by the AATS, ASE, SCAI, SCA, and STS. ## 2. General Principles ### 2.4. Basic Principles of Medical Therapy #### 2.4.2. Infective Endocarditis Prophylaxis: Recommendation With the absence of RCTs that demonstrated the efficacy of antibiotic prophylaxis to prevent infective endocarditis (IE), the practice of antibiotic prophylaxis has been questioned by national and international medical societies.11–14 Moreover, there is not universal agreement on which patient populations are at higher risk of developing IE than the general population. Protection from endocarditis in patients undergoing high-risk procedures is not guaranteed. A prospective study demonstrated that prophylaxis given to patients for what is typically considered a high-risk dental procedure reduced but did not eliminate the incidence of bacteremia.15 A 2013 Cochrane Database systematic review of antibiotic prophylaxis of IE in dentistry concluded that there is no evidence to determine whether antibiotic prophylaxis is effective or ineffective, highlighting the need for further study of this longstanding clinical dilemma.13 Epidemiological data conflict with regard to incidence of IE after adoption of more limited prophylaxis, as recommended by the AHA and European Society of Cardiology,16–20 and no prophylaxis, as recommended by the U.K. NICE (National Institute for Health and Clinical Excellence) guidelines.21 Some studies indicate no increase in incidence of endocarditis with limited or no prophylaxis, whereas others suggest that IE cases have increased with adoption of the new guidelines.16–22 The consensus of the writing group is that antibiotic prophylaxis is reasonable for the subset of patients at increased risk of developing IE and at high risk of experiencing adverse outcomes from IE. There is no evidence for IE prophylaxis in gastrointestinal procedures or genitourinary procedures, absent known active infection. ![Table2](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T2.medium.gif) [Table2](http://circ.ahajournals.org/content/135/25/e1159/T2) Recommendation for IE Prophylaxis #### 2.4.3. Anticoagulation for Atrial Fibrillation in Patients With VHD: Recommendations (New Section) ![Table3](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T3.medium.gif) [Table3](http://circ.ahajournals.org/content/135/25/e1159/T3) Recommendations for Anticoagulation for Atrial Fibrillation (AF) in Patients With VHD ## 3. Aortic Stenosis ### 3.2. Aortic Stenosis #### 3.2.4. Choice of Intervention: Recommendations The recommendations for choice of intervention for AS apply to both surgical AVR and TAVR; indications for AVR are discussed in Section 3.2.3 in the 2014 VHD guideline. The integrative approach to assessing risk of surgical AVR or TAVR is discussed in Section 2.5 in the 2014 VHD guideline. The choice of proceeding with surgical AVR versus TAVR is based on multiple factors, including the surgical risk, patient frailty, comorbid conditions, and patient preferences and values.41 Concomitant severe coronary artery disease may also affect the optimal intervention because severe multivessel coronary disease may best be served by surgical AVR and coronary artery bypass graft surgery (CABG). See Figure 1 for an algorithm on choice of TAVR versus surgical AVR. ![Figure 1.](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/F1.medium.gif) [Figure 1.](http://circ.ahajournals.org/content/135/25/e1159/F1) Figure 1. Choice of TAVR Versus Surgical AVR in the Patient With Severe Symptomatic AS. AS indicates aortic stenosis; AVR, aortic valve replacement; and TAVR, transcatheter aortic valve replacement. ![Table4](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T4.medium.gif) [Table4](http://circ.ahajournals.org/content/135/25/e1159/T4) Recommendations for Choice of Intervention ## 7. Mitral Regurgitation ### 7.2. Stages of Chronic MR In chronic *secondary* MR, the mitral valve leaflets and chords usually are normal (Table 2 in this focused update; Table 16 from the 2014 VHD guideline). Instead, MR is associated with severe LV dysfunction due to coronary artery disease (ischemic chronic secondary MR) or idiopathic myocardial disease (nonischemic chronic secondary MR). The abnormal and dilated left ventricle causes papillary muscle displacement, which in turn results in leaflet tethering with associated annular dilation that prevents adequate leaflet coaptation. There are instances in which both primary and secondary MR are present. The best therapy for chronic secondary MR is not clear because MR is only 1 component of the disease, with clinical outcomes also related to severe LV systolic dysfunction, coronary disease, idiopathic myocardial disease, or other diseases affecting the heart muscle. Thus, restoration of mitral valve competence is not curative. The optimal criteria for defining severe secondary MR have been controversial. In patients with secondary MR, some data suggest that, compared with primary MR, adverse outcomes are associated with a smaller calculated effective regurgitant orifice, possibly because of the fact that a smaller regurgitant volume may still represent a large regurgitant fraction in the presence of compromised LV systolic function (and low total stroke volume) added to the effects of elevated filling pressures. In addition, severity of secondary MR may increase over time because of the associated progressive LV systolic dysfunction and dysfunction due to adverse remodeling of the left ventricle. Finally, Doppler methods for calculations of effective regurgitant orifice area by the flow convergence method may underestimate severity because of the crescentic shape of the regurgitant orifice, and multiple parameters must be used to determine the severity of MR.67,68 Even so, on the basis of the criteria used for determination of “severe” MR in RCTs of surgical intervention for secondary MR,69–72 the recommended definition of severe secondary MR is now the same as for primary MR (effective regurgitant orifice ≥0.4 cm2 and regurgitant volume ≥60 mL), with the understanding that effective regurgitant orifice cutoff of >0.2 cm2 is more sensitive and >0.4 cm2 is more specific for severe MR. However, it is important to integrate the clinical and echocardiographic findings together to prevent unnecessary operation when the MR may not be as severe as documented on noninvasive studies. View this table: [Table 2.](http://circ.ahajournals.org/content/135/25/e1159/T5) Table 2. Stages of Secondary MR (Table 16 in the 2014 VHD Guideline) ### 7.3. Chronic Primary MR #### 7.3.3. Intervention: Recommendations ![Table6](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T6.medium.gif) [Table6](http://circ.ahajournals.org/content/135/25/e1159/T6) Recommendations for Chronic Primary MR Intervention ### 7.4. Chronic Secondary MR #### 7.4.3. Intervention: Recommendations Chronic severe secondary MR adds volume overload to a decompensated LV and worsens prognosis. However, there are only sparse data to indicate that correcting MR prolongs life or even improves symptoms over an extended time. Percutaneous mitral valve repair provides a less invasive alternative to surgery but is not approved for clinical use for this indication in the United States.70,72,125–127 The results of RCTs examining the efficacy of percutaneous mitral valve repair in patients with secondary MR are needed to provide information on this patient group.128,129 ![Figure 2.](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/F2.medium.gif) [Figure 2.](http://circ.ahajournals.org/content/135/25/e1159/F2) Figure 2. Indications for Surgery for MR (Updated Figure 4 From the 2014 VHD guideline). *MV repair is preferred over MV replacement when possible. AF indicates atrial fibrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; EF, ejection fraction; ERO, effective regurgitant orifice; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; MV, mitral valve; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx, therapy. ![Table7](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T7.medium.gif) [Table7](http://circ.ahajournals.org/content/135/25/e1159/T7) Recommendations for Secondary MR Intervention ## 11. Prosthetic Valves ### 11.1. Evaluation and Selection of Prosthetic Valves #### 11.1.2. Intervention: Recommendations ![Table8](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T8.medium.gif) [Table8](http://circ.ahajournals.org/content/135/25/e1159/T8) Recommendations for Intervention of Prosthetic Valves ### 11.2. Antithrombotic Therapy for Prosthetic Valves #### 11.2.1. Diagnosis and Follow-Up Effective oral antithrombotic therapy in patients with mechanical heart valves requires continuous VKA anticoagulation with an INR in the target range. It is preferable to specify a single INR target for each patient and to recognize that the acceptable range includes 0.5 INR units on each side of this target. A specific target is preferable because it reduces the likelihood of patients having INR values consistently near the upper or lower boundary of the range. In addition, fluctuations in INR are associated with an increased incidence of complications in patients with prosthetic heart valves, so patients and caregivers should strive to attain the specific INR value.170,171 The effects of VKA anticoagulation vary with the specific drug, absorption, various foods, alcohol, other medications, and changes in liver function. Most of the published studies of VKA therapy used warfarin, although other coumarin agents are used on a worldwide basis. In clinical practice, a program of patient education and close surveillance by an experienced healthcare professional, with periodic INR determinations, is necessary. Patient monitoring through dedicated anticoagulation clinics results in lower complication rates than those seen with standard care and is cost effective because of lower rates of bleeding and hemorrhagic complications.172,173 Periodic direct patient contact and telephone encounters174 with the anticoagulation clinic pharmacists175,176 or nurses are equally effective in reducing complication rates.177 Self-monitoring with home INR measurement devices is another option for educated and motivated patients. View this table: [Table 3.](http://circ.ahajournals.org/content/135/25/e1159/T9) Table 3. Factors Used for Shared Decision Making About Type of Valve Prosthesis #### 11.2.2. Medical Therapy: Recommendations ![Table10](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T10.medium.gif) [Table10](http://circ.ahajournals.org/content/135/25/e1159/T10) Recommendations for Antithrombotic Therapy for Patients with Prosthetic Heart Valves ### 11.3. Bridging Therapy for Prosthetic Valves #### 11.3.1. Diagnosis and Follow-Up The management of patients with mechanical heart valves for whom interruption of anticoagulation therapy is needed for diagnostic or surgical procedures should take into account the type of procedure; bleeding risk; patient risk factors; and type, location, and number of heart valve prostheses. #### 11.3.2. Medical Therapy: Recommendations ![Table11](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T11.medium.gif) [Table11](http://circ.ahajournals.org/content/135/25/e1159/T11) Recommendations for Bridging Therapy for Prosthetic Valves ### 11.6. Acute Mechanical Prosthetic Valve Thrombosis #### 11.6.1. Diagnosis and Follow-Up: Recommendation ![Table12](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T12.medium.gif) [Table12](http://circ.ahajournals.org/content/135/25/e1159/T12) Recommendation for Mechanical Prosthetic Valve Thrombosis Diagnosis and Follow-Up #### 11.6.3. Intervention: Recommendation ![Table13](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T13.medium.gif) [Table13](http://circ.ahajournals.org/content/135/25/e1159/T13) Recommendation for Mechanical Prosthetic Valve Thrombosis Intervention ### 11.7. Prosthetic Valve Stenosis Surgical reoperation to replace the stenotic prosthetic heart valve has been the mainstay treatment modality. Although it is associated with acceptable mortality and morbidity in the current era, it remains a serious clinical event and carries a higher risk than the initial surgery. Reoperation is usually required for moderate-to-severe prosthetic dysfunction (structural and nonstructural), dehiscence, and prosthetic valve endocarditis. Reoperation may also be needed for recurrent thromboembolism, severe intravascular hemolysis, severe recurrent bleeding from anticoagulant therapy, and thrombosed prosthetic valves. In 2015, catheter-based therapy with transcatheter valve-in-valve emerged as an acceptable alternative to treat high- and extreme-risk patients with bioprosthetic aortic valve stenosis (stenosis, insufficiency, or combined) in the absence of active IE.154 Symptomatic prosthetic valve stenosis secondary to thrombosis is observed predominantly with mechanical valves. Mechanical prosthetic valve thrombosis and its treatment are discussed in Section 11.6. Bioprosthetic valve thrombosis can result in thromboembolic events or obstruction. In a pooled analysis from 3 studies including 187 patients who underwent either TAVR or bioprosthetic surgical AVR, reduced leaflet motion was noted on 4-dimensional volume-rendered CT imaging in 21% of patients.203 In this small cohort, therapeutic anticoagulation with warfarin was associated with lower incidence of reduced leaflet motion than that associated with dual antiplatelet therapy, as well as more restoration of leaflet motion on follow-up CT imaging. Subclinical leaflet thrombosis was identified as the likely cause on the basis of advanced and characteristic imaging findings.203 As outlined by the US Food and Drug Administration, most cases of reduced leaflet motion (which occurs in 10% to 40% of TAVR patients and 8% to 12% of surgical AVR patients) were discovered by advanced imaging studies in asymptomatic patients.236 The diagnosis of bioprosthetic valve thrombosis remains difficult, with most suspected bioprosthetic valve thrombosis based on increased transvalvular gradients. View this table: [Table 4.](http://circ.ahajournals.org/content/135/25/e1159/T14) Table 4. Fibrinolysis Versus Surgery for ProstheticValve Thrombosis In some patients, the size of the prosthetic valve that can be implanted results in inadequate blood flow to meet the metabolic demands of the patient, even when the prosthetic valve itself is functioning normally. This situation, called *patient–prosthesis mismatch* (defined as an indexed effective orifice area ≤0.85 cm2/m2 for aortic valve prostheses), is a predictor of a high transvalvular gradient, persistent LV hypertrophy, and an increased rate of cardiac events after AVR.237,238 The impact of a relatively small valve area is most noticeable with severe patient– prosthesis mismatch, defined as an indexed orifice area <0.65 cm2/m2. Patient–prosthesis mismatch is especially detrimental in patients with reduced LVEF and may decrease the likelihood of resolution of symptoms and improvement in LVEF. Patient–prosthesis mismatch can be avoided or reduced by choice of a valve prosthesis that will have an adequate indexed orifice area, determined by the patient’s body size and annular dimension. In some cases, annular enlargement or other approaches may be needed to allow implantation of an appropriately sized valve or avoidance of a prosthetic valve. With bileaflet mechanical valves, patterns of blood flow are complex, and significant pressure recovery may be present; this may result in a high velocity across the prosthesis that should not be mistaken for prosthetic valve stenosis or patient–prosthesis mismatch, particularly in those with small aortic diameters. #### 11.7.3. Intervention: Recommendation ![Table15](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T15.medium.gif) [Table15](http://circ.ahajournals.org/content/135/25/e1159/T15) Recommendations for Prosthetic Valve Stenosis ### 11.8. Prosthetic Valve Regurgitation #### 11.8.3. Intervention: Recommendations ![Table16](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T16.medium.gif) [Table16](http://circ.ahajournals.org/content/135/25/e1159/T16) Recommendations for Prosthetic Valve Regurgitation ## 12. Infective Endocarditis ### 12.2. Infective Endocarditis #### 12.2.3. Intervention: Recommendations ![Table17](http://circ.ahajournals.org/http://circ.ahajournals.org/content/circulationaha/135/25/e1159/T17.medium.gif) [Table17](http://circ.ahajournals.org/content/135/25/e1159/T17) Recommendations for IE Intervention ## ACC/AHA Task Force Members Glenn N. Levine, MD, FACC, FAHA, Chair; Patrick T. O’Gara, MD, MACC, FAHA, Chair-Elect; Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair*; Sana M. Al-Khatib, MD, MHS, FACC, FAHA; Kim K. Birtcher, MS, PharmD, AACC; Biykem Bozkurt, MD, PhD, FACC, FAHA; Ralph G. Brindis, MD, MPH, MACC*; Joaquin E. Cigarroa, MD, FACC; Lesley H. Curtis, PhD, FAHA; Lee A. Fleisher, MD, FACC, FAHA; Federico Gentile, MD, FACC; Samuel Gidding, MD, FAHA; Mark A. Hlatky, MD, FACC; John Ikonomidis, MD, PhD, FAHA; José Joglar, MD, FACC, FAHA; Susan J. Pressler, PhD, RN, FAHA; Duminda N. Wijeysundera, MD, PhD ## Presidents and Staff ### American College of Cardiology Richard A. Chazal, MD, FACC, President Shalom Jacobovitz, Chief Executive Officer William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing ### American College of Cardiology/American Heart Association Katherine Sheehan, PhD, Director, Guideline Strategy and Operations Lisa Bradfield, CAE, Director, Guideline Methodology and Policy Abdul R. Abdullah, MD, Science and Medicine Advisor Clara Fitzgerald, Project Manager, Clinical Practice Guidelines ### American Heart Association Steven R. Houser, PhD, FAHA, President Nancy Brown, Chief Executive Officer Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations ## Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (January 2016) | Committee Member | Employment | Consultant | Speakers Bureau | Ownership/Partnership/Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness | Voting Recusals by Section* | |:--------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---------- | --------------- | ------------------------------- | ------------------------------------------------------------------------------ | --------------------------------------------------------- | -------------- | ------------------------------ | | Rick A. Nishimura, Co-Chair | Mayo Clinic, Division of Cardiovascular Disease—Judd and Mary Morris Leighton Professor of Medicine | None | None | None | None | None | None | None | | Catherine M. Otto, Co-Chair | University of Washington Division of Cardiology—Professor of Medicine | None | None | None | None | None | None | None | | Robert O. Bonow | Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Cardiology | None | None | None | None | None | None | None | | Blase A. Carabello | East Carolina University, Brody School of Medicine, East Carolina Heart Institute—Chief Cardiology Director | None | None | None | • Edwards Lifesciences (DSMB)† | • Medtronic† | | 3.2.4, 7.3.3, 7.4.3, and 11.1. | | John P. Erwin III | Texas A&M College of Medicine, Baylor Scott and White Health—Senior Staff Cardiologist, Clinical Professor and Chair of Internal Medicine | None | None | None | None | None | None | None | | Lee A. Fleisher | University of Pennsylvania, Department of Anesthesiology—Professor of Anesthesiology | None | None | None | None | None | None | None | | Hani Jneid | Baylor College of Medicine—Associate Professor of Medicine, Director of Interventional Cardiology Research; The Michael E. DeBakey VA Medical Center—Director of Interventional Cardiology | None | None | None | None | None | None | None | | Michael J. Mack | The Heart Hospital Baylor Plano—Director | None | None | None | None | • Abbott Vascular
• Edwards Lifesciences | None | 3.2.4, 7.3.3, 7.4.3, and 11.1 | | Christopher J. McLeod | Mayo Clinic, Division of Cardiovascular Disease—Assistant Professor of Medicine | None | None | None | None | None | None | None | | Patrick T. O’Gara | Brigham and Women’s Hospital—Professor of Medicine; Harvard Medical School—Director of Clinical Cardiology | None | None | | None | None | None | None | | Vera H. Rigolin | Northwestern University Feinberg School of Medicine—Professor of Medicine; Northwestern Memorial Hospital—Medical Director, Echocardiography Laboratory | None | None | None | • Pfizer | None | None | None | | Thoralf M. Sundt III | Massachusetts General Hospital—Chief, Division of Cardiac Surgery, Harvard Medical School—Professor of Surgery | None | None | None | • Edwards LifeScience—Partner trial (PI)
• Medtronic—Perigon trial (PI) | • Thrasos (Steering Committee)‡ | None | 3.2.4, 7.3.3, 7.4.3, and 11.1. | | Annemarie Thompson | Duke University Medical Center—Department of Anesthesiology, Professor of Anesthesiology; Residency Program Director | None | None | None | None | None | None | None | * This table represents relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that existwith no financial benefit are also included for the purpose of transparency. Relationships in this table aremodest unless otherwise noted. According to the ACC/AHA, a person has a *relevant* relationship IF: a) the *relationship or interest* relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the *company/entity* (with whomthe relationship exists)makes a drug, drug class, or device addressed in the document ormakes a competing drug or device addressed in the document; or c) the *person or a member of the person’s household*, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. * * Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. Section numbers pertain to those in the full-text guideline. * † No financial benefit. * ‡ Significant relationship. * ACC indicates American College of Cardiology; AHA, American Heart Association; Partner, Placement of Aortic Transcatheter Valve; Perigon, Pericardial Surgical Aortic Valve Replacement; and VA, Veterans Affairs. ## Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (September 2016) | Reviewer | Representation | Employment | Consultant | Speakers Bureau | Ownership/Partnership/Principal | Personal Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness | |:---------------------- | ------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------- | ------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------ | | Salvatore P. Costa | Official Reviewer—AHA | Dartmouth-Hitchcock Medical Center; Section of Cardiology | None | None | None | None | None | None | | Federico Gentile | Official Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines Lead Reviewer | Centro Medico Diagnostico—Director, Cardiovascular Disease | None | None | None | None | None | None | | Lawrence G. Rudski | Official Reviewer—ACC Board of Governors | Jewish General Hospital, McGill University—Professor of Medicine; Integrated Cardiovascular Sciences Program—Director | None | None | • Medtronic* | • Sanofi/Genzyme* | • GE Healthcare*
• CSE† | None | | John J. Ryan | Official Reviewer—AHA | University of Utah Health Sciences Center—Division of Cardiovascular Medicine | None | None | None | None | • Novartis | None | | David Adams | Organizational Reviewer—AATS | Mount Sinai Medical Center; Department of Cardiovascular Surgery—Professor and System Chair | None | None | None | • Medtronic
• NeoChord | • Edwards Lifesciences*
• Medtronic* | None | | Joseph E. Bavaria | Organizational Reviewer—STS | Hospital of the University of Pennsylvania; Division of Cardiovascular Surgery—Vice Chief; Thoracic Aortic Surgery Program—Director; Transcatheter Valve Program—Co-Director | None | None | None | • CyotoSorbents
• Edwards Lifesciences
• Medtronic
• St. Jude Medical
• Vascutek
• W.L. Gore | • Edwards Lifesciences
• Medtronic | None | | Wael A. Jaber | Organizational Reviewer—ASE | Cleveland Clinic Foundation, Cardiovascular Medicine, Cardiovascular Imaging Core Laboratory—Director | None | None | None | • Edwards Lifesciences | None | None | | Stanton Shernan | Organizational Reviewer—SCA | Brigham and Women’s Hospital, Cardiac Anesthesia Division—Director; Harvard Medical School—Professor | None | None | None | None | • Philips Healthcare
• National Board of Echocardiography† | None | | Molly Szerlip | Organizational Reviewer—SCAI | The Heart Group—Interventional Cardiologist; The Heart Hospital Baylor Plano—Medical Director, Inpatient and Outpatient Valve Program | • Edwards Lifesciences
• Medtronic | • Abiomed†
• Edwards Lifesciences† | None | None | • Edwards Lifesciences
• Medtronic | None | | Kim K. Birtcher | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | University of Houston College of Pharmacy—Clinical Professor | • Jones & Bartlett
• Learning | None | None | None | None | None | | Vera Bittner | Content Reviewer—ACC Prevention of Cardiovascular Disease Section Leadership Council | University of Alabama at Birmingham—Professor of Medicine; Section Head, General Cardiology, Prevention and Imaging | • Eli Lilly
• ABIM*
• Alabama ACC
• Alabama ACP | None | None | • Amgen
• AstraZeneca*
• Bayer Healthcare*
• DalCor*
• Pfizer
• Sanofi-aventis* | • National Lipid Association | None | | Emmanouil Brilakis | Content Reviewer | Laboratory, VA North Texas Healthcare System—Director Cardiac Catheterization | • Abbott Vascular*
• Asahi
• Cardinal Health
• Elsevier
• GE Healthcare
• St. Jude Medical | None | None | • Boston Scientific*
• InfraRedx* | • Abbott Vascular†
• AstraZeneca†
• Cerenis Therapeutics*
• Cordis*
• Daiichi Sankyo*
• Guerbet*
• InfraRedx*
• SCAI | None | | James Fang | Content Reviewer | University of Utah School of Medicine—Chief of Cardiovascular Medicine; University of Utah Health Care—Director, Cardiovascular Service Line | • Accordia | None | None | • Actelion (DSMB)
• Cardiocell (DSMB)
• NIH (DSMB | • CardioKinetix
• NIH
• Novartis | None | | Michael S. Firstenberg | Content Reviewer—ACC Surgeons’ Council | The Summa Health System—Thoracic and Cardiac Surgery | • Allmed*
• Johnson & Johnson
• Maquet Cardiovascular* | None | None | None | • Grisfols | None | | Annetine Gelijns | Content Reviewer | Mount Sinai Medical Center, Population Health Science and Policy—Professor and System Chair | None | None | None | None | • Icahn School of Medicine at Mount Sinai*
• NIH | None | | Samuel Gidding | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | Nemours/Alfred I. duPont Hospital for Children—Chief, Division of Pediatric Cardiology | • FH Foundation†
• International FH Foundation† | None | None | • FH Foundation†
• NIH* | None | None | | Paul A. Grayburn | Content Reviewer | Baylor Heart and Vascular Institute—Director of Cardiology Research | • Abbott Vascular*
• Tendyne | None | None | • Abbott Vascular†
• Boston Scientific†
• Medtronic†
• Tendyne†
• Valtech Cardio† | • American Journal of Cardiology
• NeoChord† | None | | Richard Grimm | Content Reviewer—ACC Heart Failure and Transplant Section Leadership Council | Cleveland Clinic Foundation, Department of Cardiovascular Medicine—Medical Director of Echo Lab | • Abbott Laboratories | None | None | None | None | None | | Jonathan L. Halperin | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | Mount Sinai Medical Center—Professor of Medicine | • AstraZeneca
• Bayer
• Boston Scientific | None | None | None | None | None | | Alex Iribarne | Content Reviewer—ACC Surgeons’ Council | Dartmouth Hitchcock Medical Center—Attending Cardiac Surgeon; Cardiac Surgical Research—Director; The Dartmouth Institute—Assistant Professor of Surgery | None | None | None | None | None | None | | Craig January | Content Reviewer | University of Wisconsin-Madison—Professor of Medicine, Cardiovascular Medicine Division | None | None | None | None | None | None | | José Joglar | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | UT Southwestern Medical Center—Associate Professor of Internal Medicine | None | None | None | None | • Medtronic*
• St. Jude Medical* | None | | Kyle W. Klarich | Content Reviewer | Mayo Clinic—Professor of Medicine | None | None | None | None | None | None | | Gautam Kumar | Content Reviewer—ACC Interventional Section Leadership Council | Emory University, Division of Cardiology—Assistant Professor of Medicine | • Abiomed
• CSI Medical
• T3 Labs
• Trireme Medical | None | None | None | • Orbus-Neich Medical
• Osprey Medical
• Stentys | None | | Richard Lange | Content Reviewer | Content Reviewer Texas Tech University Health Sciences Center at El Paso—President | None | None | None | None | None | None | | Susan T. Laing | Content Reviewer—ACC Heart Failure and Transplant Section Leadership Council | UT Health Science Center at Houston (UT Health)—Professor of Medicine, Division of Cardiology, Associate Chief; Director of Echocardiography | None | None | None | None | None | None | | Glenn Levine | Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines | Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit | None | None | None | None | None | • Defendant, Hospital Death, 2016
• Defendant, Catheterization Laboratory Procedure, 2016 | | Brian Lindman | Content Reviewer | Washington University School of Medicine in St. Louis, Cardiovascular Division—Associate Professor of Medicine | • Roche Diagnostics | None | None | • AHA Clinical Research Grant*
• Barnes-Jewish Hospital Foundation*
• Doris Duke Charitable Foundation*
• Edwards Lifesciences*
• NIH
• Roche
• Diagnostics* | • NIH* | None | | D. Craig Miller | Content Reviewer | Stanford University Medical Center—Cardiothoracic Surgeon | • Medtronic
• NHLBI | None | None | • Abbott Laboratories
• Edwards Lifesciences
• Medtronic | None | None | | Stefano Nistri | Content Reviewer | CMSR Veneto Medica—Chief, Cardiology Service | None | None | None | None | None | None | | Philippe Pibarot | Content Reviewer | Université Laval—Professor of Medicine; Canada Research in Valvular Heart Diseases | None | None | None | • Cardiac Phoenix*
• Edwards Lifesciences*
• Medtronic*
• V-Wave*
• Canadian Institute of Health | None | None | | Hartzell V. Schaff | Content Reviewer | Mayo Clinic—Professor of Surgery | None | None | None | None | None | None | | Allan Schwartz | Content Reviewer | Columbia University Medical Center—Chief, Division of Cardiology, Vice Chair of Department of Medicine | None | None | None | None | None | None | | Karen Stout | Content Reviewer | University of Washington—Director, Adult Congenital Heart Disease Program, Professor, Internal Medicine and Pediatrics | None | None | None | None | None | None | | Rakesh Suri | Content Reviewer | Cleveland Clinic Foundation—Professor of Surgery, Department of Thoracic and Cardiovascular Surgery | • Sorin† Abbott | None | None | • St. Jude Medical | • St. Jude Medical | None | | Vinod Thourani | Content Reviewer | Emory University School of Medicine, Division of Cardiothoracic Surgery— Professor of Surgery; Structural Heart and Valve Center of the Emory Heart and Vascular Center—Co-Director; Emory University Hospital Midtown—Chief of Cardiothoracic Surgery | • Edwards Lifesciences
• St. Jude Medical | None | None | • Abbott Medical
• Boston Scientific†
• Edwards Lifesciences†
• Medtronic† | None | None | | E. Murat Tuzcu | Content Reviewer | Cleveland Clinic Abu Dhabi—Cardiovascular Medicine | None | None | None | None | • Boston Scientific
• Direct Flow Medical
• St. Jude Medical
• Tendyne | None | | Andrew Wang | Content Reviewer | Duke University Medical Center—Professor of Medicine; Cardiovascular Disease Fellowship Program—Director | • Heart Metabolics*
• ACP* | None | None | None | • Abbott Vascular*
• Gilead Sciences*
• Maokardia*
• Edwards Lifesciences
• Medtronic | None | | L. Samuel Wann | Content Reviewer | Columbia St. Mary’s Cardiovascular Physicians—Clinical Cardiologist | • United Healthcare | None | None | None | None | None | | Frederick Welt | Content Reviewer—ACC Interventional Section Leadership Council | University of Utah Health Sciences Center, Division of Cardiology—Director, Interventional Cardiology | • Medtronic | None | None | None | • Athersys
• Capricor
• CardioKinetix
• Medtronic
• Renova Therapeutics
• Siemens
• Teva Pharmaceuticals
• Washington University | None | * This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to [http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy](http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy) for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. * * Significant relationship. * † No financial benefit. * AAFP indicates American Academy of Family Physicians; AATS, American Association for Thoracic Surgery; ABIM, American Board of Internal Medicine; ACC, American College of Cardiology; ACP, American College of Physicians; AHA, American Heart Association; ASE, American Society of Echocardiography; CSE, Canadian Society of Echocardiography; DSMB, data safety monitoring board; FH, familial hyperlipidemia; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; SCAI, Society for Cardiovascular Angiography and Interventions; SCA, Society of Cardiovascular Anesthesiologists; STS, Society of Thoracic Surgeons; UT, University of Texas; and WVU, West Virginia University. ## Appendix 3. Abbreviations | AF = atrial fibrillation | || | AS = aortic stenosis | | AVR = aortic valve replacement | | CABG = coronary artery bypass graft surgery | | CI = confidence interval | | CT = computed tomography | | DOACs = direct oral anticoagulants | | EF = ejection fraction | | GDMT = guideline-directed management and therapy | | HF = heart failure | | HR= hazard ratio | | IE = infective endocarditis | | INR = International Normalized Ratio | | LV = left ventricular | | LVEF = left ventricular ejection fraction | | LVESD = left ventricular end-systolic diameter | | MR = mitral regurgitation | | MS = mitral stenosis | | MVR = mitral valve replacement | | NYHA = New York Heart Association | | RCT = randomized controlled trial | | TAVR = transcatheter aortic valve replacement | | VHD = valvular heart disease | | VKA = vitamin K antagonist | ## Footnotes * The American Heart Association requests that this document be cited as follows: Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017;135:e1159–e1195. DOI: 10.1161/CIR.0000000000000503. * This document was approved by the American College of Cardiology Clinical Policy Approval Committee on behalf of the Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee in January 2017, and the American Heart Association Executive Committee in February 2017. * The online Comprehensive RWI Data Supplement table is available with this article at [http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC1). * The online Data Supplement is available with this article at [http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC2](http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000503/-/DC2). * This article has been copublished in the *Journal of the American College of Cardiology*. * Copies: This document is available on the World Wide Web sites of the American Heart Association (professional.heart.org) and the American College of Cardiology ([www.acc.org](http://www.acc.org)). A copy of the document is available at [http://professional.heart.org/statements](http://professional.heart.org/statements) by using either “Search for Guidelines & Statements” or the “Browse by Topic” area. To purchase additional reprints, call 843-216-2533 or e-mail [kelle.ramsay@wolterskluwer.com](http://kelle.ramsay@wolterskluwer.com). * Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit [http://professional.heart.org/statements](http://professional.heart.org/statements). Select the “Guidelines & Statements” drop-down menu, then click “Publication Development.” * Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at [http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines\_UCM\_300404\_Article.jsp](http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp). A link to the “Copyright Permissions Request Form” appears on the right side of the page. * *Circulation* is available at [http://circ.ahajournals.org](http://circ.ahajournals.org). * * Former Task Force member; current member during the writing effort. * © 2017 by the American Heart Association, Inc., and the American College of Cardiology Foundation. ## References 1. 1.Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.). Clinical Practice Guidelines We Can Trust. ed. Washington, DC: Press NA, 2011. 2. 2.Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. ed. Washington, DC: Press NA, 2011. 3. 3.Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=129/22/2329&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 4. 4.ACCF/AHA Task Force on Practice Guidelines Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association2010. Available at: [http://assets.cardiosource.com/Methodology\_Manual\_for\_ACC\_AHA\_Writing\_Committees.pdf](http://assets.cardiosource.com/Methodology\_Manual\_for\_ACC_AHA_Writing_Committees.pdf). Accessed February 2017. 5. 5.Halperin JL, Levine GN, Al-Khatib SM, Birtcher K, Bozkurt B. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426–28. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=133/14/1426&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 6. 6.Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268–310. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=127/2/268&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 7. 7.Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:1208–17. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=130/14/1208&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 8. 8.Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. Circulation. 2014;130:1662–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=130/18/1662&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 9. 9.Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–92. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=129/23/2440&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 10. 10.Nishimura R, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521–643. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=129/23/e521&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 11. 11.Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736–54. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=116/15/1736&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 12. 12.Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:3075–128. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=ehj&resid=36/44/3075&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 13. 13.Glenny AM, Oliver R, Roberts GJ, Hooper L, Worthington HV. Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev. 2013:CD003813. 14. 14.(NICE) UNIfHaCE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Available at: [https://www.nice.org.uk/guidance/cg64](https://www.nice.org.uk/guidance/cg64). Accessed January 20, 2017. 15. 15.Mougeot FKB, Saunders SE, Brennan MT, Lockhart PB. Associations between bacteremia from oral sources and distant-site infections: tooth brushing versus single tooth extraction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:430–5. 16. 16.Desimone DC, Tleyjeh IM, Correa de Sa DD, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association’s endocarditis prevention guidelines. Circulation. 2012;126:60–4. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=126/1/60&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 17. 17.Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet. 2015;385:1219–28. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(14)62007-9&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25467569&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 18. 18.Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol. 2012;59:1968–76. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=59/22/1968&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 19. 19.Pasquali SK, He X, Mohamad Z, et al. Trends in endocarditis hospitalizations at US children’s hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J. 2012;163:894–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2012.03.002&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22607869&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 20. 20.Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol. 2015;65:2070–6. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=65/19/2070&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 21. 21.Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011;342:d2392. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=bmj&resid=342/may03_1/d2392&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 22. 22.Strom BL, Abrutyn E, Berlin JA, et al. Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation. 2000;102:2842–8. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=102/23/2842&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 23. 23.Sherman-Weber S, Axelrod P, Suh B, et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis. 2004;6:165–70. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1111/j.1399-3062.2004.00074.x&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15762934&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 24. 24.Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK. Bacteremia associated with toothbrushing and dental extraction. Circulation. 2008;117:3118–25. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=117/24/3118&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 25. 25.Geist SM, Fitzpatrick S, Geist JR. American Heart Association 2007 guidelines on prevention of infective endocarditis. J Mich Dent Assoc. 2007;89:50–6. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17844678&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 26. 26.Duval X, Alla F, Hoen B, et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis. 2006;42:e102–7. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cid&resid=42/12/e102&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 27. 27.The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36:3036–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=ehj&resid=36/44/3036&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 28. 28.Horstkotte D, Rosen H, Friedrichs W, Loogen F. Contribution for choosing the optimal prophylaxis of bacterial endocarditis. Eur Heart J. 1987;8 suppl J:379–81. [Abstract](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=8/suppl_J/379&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 29. 29.Strom BL, Abrutyn E, Berlin JA, et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med. 1998;129:761–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.7326/0003-4819-129-10-199811150-00002&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9841581&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000076984800001&link_type=ISI) 30. 30.Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015;131:1566–74. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=131/18/1566&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 31. 31.Mangner N, Woitek F, Haussig S, et al. Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2907–8. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=67/24/2907&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 32. 32.Karavas AN, Filsoufi F, Mihaljevic T, Aranki SF, Cohn LH, Byrne JG. Risk factors and management of endocarditis after mitral valve repair. J Heart Valve Dis. 2002;11:660–4. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12358402&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 33. 33.Gillinov AM, Faber CN, Sabik JF, et al. Endocarditis after mitral valve repair. Ann Thorac Surg. 2002;73:1813–6. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(02)03551-8&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12078774&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000175995300027&link_type=ISI) 34. 34.Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44:1557–66. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=44/8/1557&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 35. 35.Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;209:181–3. 36. 36.Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624–32. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=132/8/624&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 37. 37.Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35:3377–85. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=35/47/3377&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 38. 38.Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016;134:589–98. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=134/8/589&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 39. 39.Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;CD001927. 40. 40.Olesen JB, Lip GY.H, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=bmj&resid=342/jan31_1/d124&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 41. 41.Lytvyn L, Guyatt GH, Manja V, et al. Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review. BMJ Open. 2016;6:e014327. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=bmjopen&resid=6/9/e014327&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 42. 42.Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988;9 Suppl E:57–64. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=9/suppl_E/57&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 43. 43.O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. Ann Thorac Surg. 2009;88:S23–42. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2009.05.056&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19559823&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000267469100003&link_type=ISI) 44. 44.Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316–26. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=111/24/3316&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 45. 45.Kvidal P, Bergström R, Hörte LG, Stahle E. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35:747–56. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=35/3/747&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 46. 46.Murphy ES, Lawson RM, Starr A, Rahimtoola SH. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation. 1981;64:II184–8. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=7249320&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 47. 47.Rosenhek R. Arotic stenosis: disease severity, progression, timing of intervention and role in monitoring transcatheter valve implanation. C.M OttoThe Practice of Clinical Echocardiography 4 ed 2012 Elsevier/SaundersPhiladelphia, PA425–49. 48. 48.Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation. 1982;66:1105–10. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=66/5/1105&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 49. 49.Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1400590&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24678937&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000335997900007&link_type=ISI) 50. 50.Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2477–84. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(15)60308-7&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25788234&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 51. 51.Deeb GM, Reardon MJ, Chetcuti S, et al. Three-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67:2565–74. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=67/22/2565&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 52. 52.Holmes DR Jr., Nishimura RA, Grover FL, et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol. 2015;66:2813–23. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=66/25/2813&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 53. 53.Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–704. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1202277&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22443478&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000303434300009&link_type=ISI) 54. 54.Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1103510&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21639811&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000291392100005&link_type=ISI) 55. 55.Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J. 2011;32:191–7. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=32/2/191&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 56. 56.Rodés-Cabau J, Webb JG, Cheung A, et al. Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol. 2012;60:1864–75. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=60/19/1864&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 57. 57.Abdel-Wahab M, Neumann FJ, Mehilli J, et al. One-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: results from the CHOICE randomized clinical trial. J Am Coll Cardiol. 2015;66:791–800. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=66/7/791&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 58. 58.Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485–91. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(15)60290-2&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25788231&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 59. 59.Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–81. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=63/19/1972&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 60. 60.Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1008232&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20961243&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000283242700004&link_type=ISI) 61. 61.Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686–95. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1200384&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22443479&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000303434300008&link_type=ISI) 62. 62.Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1514616&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=27040324&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 63. 63.Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–25. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(16)30073-3&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=27053442&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 64. 64.Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. BMJ. 2016;356:i5130. 65. 65.Foroutan F, Guyatt GH, O’Brien K, et al. Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ. 2016;354:i5065. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=bmj&resid=354/sep28_7/i5065&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 66. 66.Vandvik PO, Otto CM, Siemieniuk RA, et al. Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline. BMJ. 2016;354:i5085. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=bmj&resid=354/sep28_11/i5085&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 67. 67.Uretsky S, Gillam L, Lang R, et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol. 2015;65:1078–88 [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=65/11/1078&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 68. 68.Grayburn PA, Carabello B, Hung J, et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 2014;64:2792–801. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=64/25/2792&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 69. 69.Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014;370:23–32 [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1312808&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24245543&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000329354100007&link_type=ISI) 70. 70.Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374:344–53. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1512913&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26550689&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 71. 71.Michler RE, Smith PK, Parides MK, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2016;374:1932–41. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1602003&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=27040451&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 72. 72.Smith PK, Puskas JD, Ascheim DD, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371:2178–88. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1410490&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25405390&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000345976700006&link_type=ISI) 73. 73.David TE, Armstrong S, McCrindle BW, Manlhiot C. Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation. 2013;127:1485–92. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=127/14/1485&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 74. 74.Gillinov AM, Mihaljevic T, Blackstone EH, et al. Should patients with severe degenerative mitral regurgitation delay surgery until symptoms develop?. Ann Thorac Surg. 2010;90:481–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2010.03.101&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20667334&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000280575100017&link_type=ISI) 75. 75.Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation. 1999;99:400–5. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=99/3/400&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 76. 76.Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation. 1990;81:1173–81. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=81/4/1173&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 77. 77.Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol. 1994;24:1536–43. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=24/6/1536&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 78. 78.Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol. 1999;34:2078–85. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=34/7/2078&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 79. 79.Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. J Am Coll Cardiol Img. 2008;1:133–41. 80. 80.Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation. 1979;59:1218–31 [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=circulationaha&resid=59/6/1218&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 81. 81.Starling MR. Effects of valve surgery on left ventricular contractile function in patients with long-term mitral regurgitation. Circulation. 1995;92:811–8. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=92/4/811&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 82. 82.Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol. 2009;54:1961–8. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=54/21/1961&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 83. 83.STS online risk calculator. Available at: [http://riskcalcstsorg/stswebriskcalc](http://riskcalcstsorg/stswebriskcalc) Accessed January 20, 2017. 84. 84.Braunberger E, Deloche A, Berrebi A, et al. Very long-term results (more than 20 years) of valve repair with Carpentier’s techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104:I8–1. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1161/01.CIR.104.2.e8&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=11568021&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000171201500002&link_type=ISI) 85. 85.Cohn LH. Surgery for mitral regurgitation. JAMA. 1988;260:2883–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.1988.03410190131036&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=3054183&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 86. 86.Cosgrove DM, Chavez AM, Lytle BW, et al. Results of mitral valve reconstruction. Circulation. 1986;74:I82–7. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=3742777&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 87. 87.David TE, Uden DE, Strauss HD. The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. Circulation. 1983;68:II76–82. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1161/01.CIR.68.1.76&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=6872199&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 88. 88.David TE, Burns RJ, Bacchus CM, Druck MN. Mitral valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg. 1984;88:718–25. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=6492840&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1984TS47400009&link_type=ISI) 89. 89.David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg. 2005;130:1242–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2005.06.046&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16256774&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000233120100002&link_type=ISI) 90. 90.Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87:1431–7; discussion 7–349. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2009.01.064&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19379881&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000265299100018&link_type=ISI) 91. 91.Goldman KE. Dental management of patients with bone marrow and solid organ transplantation. Dent Clin North Am. 2006;50:659–76viii. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17000279&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 92. 92.Hansen DE, Sarris GE, Niczyporuk MA, Derby GC, Cahill PD, Miller DC. Physiologic role of the mitral apparatus in left ventricular regional mechanics, contraction synergy, and global systolic performance. J Thorac Cardiovasc Surg. 1989;97:521–33. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=2927157&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1989U041800006&link_type=ISI) 93. 93.Hennein HA, Swain JA, McIntosh CL, Bonow RO, Stone CD, Clark RE. Comparative assessment of chordal preservation versus chordal resection during mitral valve replacement. J Thorac Cardiovasc Surg. 1990;99:828–36; discussion 36–7. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=2329820&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1990DB98500007&link_type=ISI) 94. 94.Horskotte D, Schulte HD, Bircks W, Strauer BE. The effect of chordal preservation on late outcome after mitral valve replacement: a randomized study. J Heart Valve Dis. 1993;2:150–8. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8261152&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 95. 95.McClure RS, Athanasopoulos LV, McGurk S, Davidson MJ, Couper GS, Cohn LH. One thousand minimally invasive mitral valve operations: early outcomes, late outcomes, and echocardiographic follow-up. J Thorac Cardiovasc Surg. 2013;145:1199–206. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2012.12.070&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=23353109&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 96. 96.Rozich JD, Carabello BA, Usher BW, Kratz JM, Bell AE, Zile MR. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation. 1992;86:1718–26. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=86/6/1718&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 97. 97.Rushmer RF. Initial phase of ventricular systole: asynchronous contraction. Am J Physiol. 1956;184:188–94. 98. 98.Sarris GE, Cahill PD, Hansen DE, Derby GC, Miller DC. Restoration of left ventricular systolic performance after reattachment of the mitral chordae tendineae. The importance of valvular-ventricular interaction. J Thorac Cardiovasc Surg. 1988;95:969–79. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=3374162&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1988N785100003&link_type=ISI) 99. 99.Vassileva CM, Mishkel G, McNeely C, et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation. 2013;127:1870–6. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=127/18/1870&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 100.100.Badhwar V, Peterson ED, Jacobs JP, et al. Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg. 2012;94:1870–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2012.05.105&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22858278&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000311436300024&link_type=ISI) 101.101.Bolling SF, Li S, O’Brien SM, Brennan JM, Prager RL, Gammie JS. Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg. 2010;90:1904–11; discussion 12. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2010.07.062&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21095334&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000284463200032&link_type=ISI) 102.102.Chauvaud S, Fuzellier JF, Berrebi A, Deloche A, Fabiani JN, Carpentier A. Long-term (29 years) results of reconstructive surgery in rheumatic mitral valve insufficiency. Circulation. 2001;104:I12–5. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=11568022&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000171201500003&link_type=ISI) 103.103.Chikwe J, Goldstone AB, Passage J, et al. A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J. 2011;32:618–26. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=32/5/618&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 104.104.Grossi EA, Galloway AC, Miller JS, et al. Valve repair versus replacement for mitral insufficiency: when is a mechanical valve still indicated?. J Thorac Cardiovasc Surg. 1998;115:389–96. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0022-5223(98)70283-1&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9475534&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000071931000030&link_type=ISI) 105.105.Gillinov AM, Blackstone EH, Cosgrove DM III., et al. Mitral valve repair with aortic valve replacement is superior to double valve replacement. J Thorac Cardiovasc Surg. 2003;125:1372–87. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0022-5223(02)73225-X&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12830057&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000183864700025&link_type=ISI) 106.106.Suri RM, Vanoverschelde JL, Grigioni F, et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013;310:609–16. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2013.8643&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=23942679&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000323058400016&link_type=ISI) 107.107.Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006;113:2238–44. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=113/18/2238&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 108.108.Gillinov AM, Blackstone EH, Nowicki ER, et al. Valve repair versus valve replacement for degenerative mitral valve disease. J Thorac Cardiovasc Surg. 2008;135:885–9393.e1–2. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2007.11.039&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18374775&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000254423600026&link_type=ISI) 109.109.Duran CM, Gometza B, Saad E. Valve repair in rheumatic mitral disease: an unsolved problem. J Card Surg. 1994;9:282–5. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1111/j.1540-8191.1994.tb00942.x&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8186582&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 110.110.Suri RM, Schaff HV, Dearani JA, et al. Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg. 2009;137:1071–6. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2008.10.026&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19379969&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000265299000005&link_type=ISI) 111.111.Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation. 2009;119:797–804. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=119/6/797&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 112.112.Tribouilloy C, Rusinaru D, Szymanski C, et al. Predicting left ventricular dysfunction after valve repair for mitral regurgitation due to leaflet prolapse: additive value of left ventricular end-systolic dimension to ejection fraction. Eur J Echocardiogr. 2011;112:702–10. 113.113.Enriquez-Sarano M, Suri RM, Clavel MA, et al. Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation. J Thorac Cardiovasc Surg. 2015;150:50–8. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25986494&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 114.114.Quintana E, Suri RM, Thalji NM, et al. Left ventricular dysfunction after mitral valve repair—the fallacy of “normal” preoperative myocardial function. J Thorac Cardiovasc Surg. 2014;148:2752–60. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2014.07.029&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25173130&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 115.115.Suri RM, Schaff HV, Dearani JA, et al. Determinants of early decline in ejection fraction after surgical correction of mitral regurgitation. J Thorac Cardiovasc Surg. 2008;136:442–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2007.10.067&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18692655&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000258535300029&link_type=ISI) 116.116.Naji P, Griffin BP, Barr T, et al. Importance of exercise capacity in predicting outcomes and determining optimal timing of surgery in significant primary mitral regurgitation. J Am Heart Assoc. 2014;3:e001010 [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ahaoa&resid=3/5/e001010&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 117.117.Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg. 1991;101:584–92. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=2008096&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1991FF24600002&link_type=ISI) 118.118.Ghoreishi M, Evans CF, DeFilippi CR, et al. Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg. 2011;142:1439–52. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2011.08.030&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21962906&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000297214200021&link_type=ISI) 119.119.Kawaguchi AT, Kosakai Y, Sasako Y, Eishi K, Nakano K, Kawashima Y. Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol. 1996;28:985–90. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=28/4/985&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 120.120.Kobayashi J, Kosakai Y, Isobe F, et al. Rationale of the Cox Maze procedure for atrial fibrillation during redo mitral valve operations. J Thorac Cardiovasc Surg. 1996;112:1216–21; discussion 22. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0022-5223(96)70134-4&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8911317&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 121.121.Ngaage DL, Schaff HV, Mullany CJ, et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified?. Ann Thorac Surg. 2007;84:434–42; discussion 42–3. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2007.04.036&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17643612&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000248192400011&link_type=ISI) 122.122.Olasinska-Wisniewska A, Mularek-Kubzdela T, Grajek S, et al. Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. Ann Thorac Surg. 2012;93:1449–55. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2011.12.034&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22459545&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 123.123.Raine D, Dark J, Bourke JP. Effect of mitral valve repair/replacement surgery on atrial arrhythmia behavior. J Heart Valve Dis. 2004;13:615–21. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15311868&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 124.124.Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1009355&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21463154&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000289467200004&link_type=ISI) 125.125.Fattouch K, Guccione F, Sampognaro R, et al. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg. 2009;364:278–85. 126.126.Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012;59:130–9. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=59/2/130&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 127.127.Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45:381–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=45/3/381&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 128.128.Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65:1231–48. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=65/12/1231&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 129.129.Obadia JF, Armoiry X, Iung B, et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention. 2015;10:1354–60. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.4244/EIJV10I11A232&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25798568&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 130.130.Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=103/13/1759&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 131.131.Lancellotti P, Gérard PL, Piérard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005;26:1528–32. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=26/15/1528&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 132.132.Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003;91:538–43. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0002-9149(02)03301-5&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12615256&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000181537800005&link_type=ISI) 133.133.Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. 2011;97:1675–80. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=heartjnl&resid=97/20/1675&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 134.134.Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. 2007;49:2191–201. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=49/22/2191&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 135.135.Harris KM, Sundt TM III., Aeppli D, Sharma R, Barzilai B. Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?. Ann Thorac Surg. 2002;74:1468–75. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(02)03920-6&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12440594&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000179262300012&link_type=ISI) 136.136.Benedetto U, Melina G, Roscitano A, et al. Does combined mitral valve surgery improve survival when compared to revascularization alone in patients with ischemic mitral regurgitation? A meta-analysis on 2479 patients. J Cardiovasc Med (Hagerstown). 2009;10:109–14. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.2459/JCM.0b013e32831c84b0&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19377377&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 137.137.Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125:2639–48. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=125/21/2639&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 138.138.Cohn LH, Rizzo RJ, Adams DH, et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: operative and late risks of repair versus replacement. Eur J Cardiothorac Surg. 1995;9:568–74. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ejctsurg&resid=9/10/568&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 139.139.Chan KMJ, Punjabi PP, Flather M, et al. Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation. 2012;126:2502–10. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=126/21/2502&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 140.140.Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2013;64:182–92. 141.141.van Geldorp MW.A, Eric Jamieson WR, Kappetein AP, et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc Surg. 2009;137:881–66e1–5. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2008.09.028&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19327512&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000264562000014&link_type=ISI) 142.142.Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50–69 years. Eur Heart J. 2016;37:2658–67. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=37/34/2658&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 143.143.Chikwe J, Chiang YP, Egorova NN, Itagaki S, Adams DH. Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years. JAMA. 2015;313:1435–42. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25871669&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 144.144.McClure RS, McGurk S, Cevasco M, et al. Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2014;148:1931–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2013.12.042&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24521965&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 145.145.Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA. 2014;312:1323–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2014.12679&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25268439&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 146.146.Repack A, Ziganshin BA, Elefteriades JA, Mukherjee SK. Comparison of quality of life perceived by patients with bioprosthetic versus mechanical valves after composite aortic root replacement. Cardiology. 2016;133:3–9. 147.147.Dunning J, Gao H, Chambers J, et al. Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use—an analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg. 2011;142:776–82.e3. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2011.04.048&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21924147&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000295255700008&link_type=ISI) 148.148.Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol. 2010;55:2413–26 [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=55/22/2413&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 149.149.Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thorac Cardiovasc Surg. 2012;144:1075–83. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2012.01.024&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22341653&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000310197900019&link_type=ISI) 150.150.Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015;99:831–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2014.09.030&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25583467&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 151.151.Bourguignon T, Bouquiaux-Stablo AL, Loardi C, et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg. 2014;148:2004–11.e1. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2014.02.050&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24667021&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 152.152.Ye J, Cheung A, Yamashita M, et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an eight-year single-center experience. J Am Coll Cardiol Intv. 2015;8:1735–44. 153.153.Dvir D, Webb J, Brecker S, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation. 2012;126:2335–44 [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=126/19/2335&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 154.154.Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312:162–70. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2014.7246&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=25005653&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000338511200022&link_type=ISI) 155.155.Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36:1152–8. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=36/4/1152&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 156.156.Chan V, Jamieson WR.E, Germann E, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. J Thorac Cardiovasc Surg. 2006;131:1267–73. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2005.11.052&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16733156&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000238023300013&link_type=ISI) 157.157.Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014;147:117–26. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2013.08.028&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24079878&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000329722600023&link_type=ISI) 158.158.Badhwar V, Ofenloch JC, Rovin JD, van Gelder HM, Jacobs JP. Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg. 2012;93:748–53. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2011.12.032&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22364968&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000300832700022&link_type=ISI) 159.159.Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg. 2008;135:878–84; discussion 84. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2007.10.065&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18374773&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000254423600025&link_type=ISI) 160.160.Kulik A, Bédard P, Lam BK, et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg. 2006;30:485–91. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ejctsurg&resid=30/3/485&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 161.161.Bourguignon T, El Khoury R, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 60 or younger. Ann Thorac Surg. 2015;100:853–9. 162.162.McClure RS, Narayanasamy N, Wiegerinck E, et al. Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. Ann Thorac Surg. 2010;89:1410–6. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2010.01.046&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20417753&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000276991200010&link_type=ISI) 163.163.Banbury MK, Cosgrove DM III., Thomas JD, et al. Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg. 2002;73:1460–5. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(02)03445-8&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12025820&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000175513100022&link_type=ISI) 164.164.Borger MA, Ivanov J, Armstrong S, Christie-Hrybinsky D, Feindel CM, David TE. Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis. 2006;15:49–55; discussion 6. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16480012&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000234639300012&link_type=ISI) 165.165.Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2002;124:146–54. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1067/mtc.2002.121672&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12091820&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000176808200022&link_type=ISI) 166.166.Mykén PS, Bech-Hansen O. A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg. 2009;137:76–81. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2008.05.068&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19154907&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000262611100014&link_type=ISI) 167.167.Charitos EI, Takkenberg JJ.M, Hanke T, et al. Reoperations on the pulmonary autograft and pulmonary homograft after the Ross procedure: an update on the German Dutch Ross Registry. J Thorac Cardiovasc Surg. 2012;144:813–21; discussion 21–3. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2012.07.005&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22883549&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000309111600014&link_type=ISI) 168.168.El-Hamamsy I, Eryigit Z, Stevens LM, et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet. 2010;376:524–31. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(10)60828-8&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20684981&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000281266800031&link_type=ISI) 169.169.Mokhles MM, Rizopoulos D, Andrinopoulou ER, et al. Autograft and pulmonary allograft performance in the second post-operative decade after the Ross procedure: insights from the Rotterdam Prospective Cohort Study. Eur Heart J. 2012;33:2213–24. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=33/17/2213&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 170.170.Edmunds LH Jr.. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg. 1987;44:430–45. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(10)63816-7&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=3310938&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1987K491900024&link_type=ISI) 171.171.Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff HV. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc. 1998;73:665–80. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.4065/73.7.665&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9663198&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000074598400011&link_type=ISI) 172.172.Aziz F, Corder M, Wolffe J, Comerota AJ. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg. 2011;54:1404–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jvs.2011.05.021&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21741791&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 173.173.Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/archinte.158.15.1641&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9701098&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000075234500009&link_type=ISI) 174.174.Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest. 2006;134:1385–9. 175.175.Lalonde L, Martineau J, Blais N, et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J. 2008;156:148–54. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2008.02.009&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18585510&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000257329900021&link_type=ISI) 176.176.Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515–22. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.127.5.1515&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15888822&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000228987600013&link_type=ISI) 177.177.Locke C, Ravnan SL, Patel R, Uchizono JA. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy. 2005;25:685–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1592/phco.25.5.685.63582&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15899730&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 178.178.Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S–600. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.11-2305&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22315272&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000208839900016&link_type=ISI) 179.179.Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635–41. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=89/2/635&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 180.180.Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJM199507063330103&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=7776988&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1995RG73500003&link_type=ISI) 181.181.Schlitt A, von Bardeleben RS, Ehrlich A, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res. 2003;109:131–5. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0049-3848(03)00143-9&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12706642&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000182987500009&link_type=ISI) 182.182.Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119:220S–7S. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.119.1_suppl.220S&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=11157651&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000166812000014&link_type=ISI) 183.183.Sun JCJ, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009;374:565–76. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0140-6736(09)60780-7&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19683642&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000269019400024&link_type=ISI) 184.184.Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94:2107–12. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=94/9/2107&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 185.185.Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest. 2005;127:53–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.127.1.53&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15653962&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000226365200013&link_type=ISI) 186.186.Torella M, Torella D, Chiodini P, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the “LOWERING-IT” Trial. Am Heart J. 2010;160:171–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2010.05.005&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20598989&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000279440400026&link_type=ISI) 187.187.Horstkotte D, Scharf RE, Schultheiss HP. Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis. 1995;4:114–20. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8556170&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 188.188.Pruefer D, Dahm M, Dohmen G, Horstkotte D, Bergemann R, Oelert H. Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5). Eur Heart J Suppl. 2001;3 Suppl Q:Q39–43. 189.189.Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg. 1997;113:910–6 [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0022-5223(97)70264-2&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9159625&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1997WZ62100015&link_type=ISI) 190.190.Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJM199308193290802&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8336751&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1993LR89200002&link_type=ISI) 191.191.Aramendi JI, Mestres CA, Campos V, Martinez-Leon J, Munoz G, Navas C. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg. 2005;27:854–60. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ejctsurg&resid=27/5/854&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 192.192.Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007;16:667–71. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18095518&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000251266300020&link_type=ISI) 193.193.Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25:1111–9. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=25/5/1111&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 194.194.Nuñez L, Gil Aguado M, Larrea JL, Celemin D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg. 1984;37:84–7. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(10)60717-5&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=6691742&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1984SA08000014&link_type=ISI) 195.195.Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol. 2012;60:971–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=60/11/971&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 196.196.Egbe AC, Pislaru SV, Pellikka PA, et al. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol. 2015;66:2285–94. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=66/21/2285&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 197.197.Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118–25. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2012.54506&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=23188028&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000311537200026&link_type=ISI) 198.198.Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa0905561&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19717844&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000269828000005&link_type=ISI) 199.199.Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1501035&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26095867&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 200.200.Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1300615&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=23991661&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000324888200007&link_type=ISI) 201.201.Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1310907&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24251359&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000327467500007&link_type=ISI) 202.202.Granger CB, Alexander JH, McMurray JJ.V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1107039&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21870978&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000294857300006&link_type=ISI) 203.203.Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1509233&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26436963&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 204.204.Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1009638&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21830957&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000294595600004&link_type=ISI) 205.205.Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg. 2005;129:1024–31. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2004.11.028&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15867776&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000228947200011&link_type=ISI) 206.206.Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol. 2008;51:1203–11. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=51/12/1203&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 207.207.ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?. J Thorac Cardiovasc Surg. 2010;139:1137–45. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2009.10.064&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20303508&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 208.208.Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134:e123–55. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=134/10/e123&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 209.209.Puskas J, Gerdisch M, Nichols D, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202–10; discussion 10–1. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.jtcvs.2014.01.004&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=24512654&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000332772200028&link_type=ISI) 210.210.Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–69. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=68/19/2059&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 211.211.Pache G, Schoechlin S, Blanke P, et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263–71. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=37/28/2263&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 212.212.FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. December 19, 2012. 2012. 213.213.Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163:931–7.e1. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2012.03.011&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22709744&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000305428200003&link_type=ISI) 214.214.Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Erratum. Chest. 2012;141:e326S–350. 215.215.Pengo V, Palareti G, Cucchini U, et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clin Appl Thromb Hemost. 2007;13:241–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1177/1076029607302544&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17636186&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 216.216.Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quinones MA, Zoghbi WA. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol. 1998;32:1410–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=32/5/1410&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 217.217.Gündüz S, özkan M, Kalçik M, et al. Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve dysfunction: thrombus or pannus. Circ Cardiovasc Imaging. 2015;8:e003246. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circcvim&resid=8/12/e003246&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 218.218.Cianciulli TE, Lax JA, Beck MA, et al. Cinefluoroscopic assessment of mechanical disc prostheses: its value as a complementary method to echocardiography. J Heart Valve Dis. 2005;14:664–73. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16245506&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000232082400016&link_type=ISI) 219.219.Montorsi P, De Bernardi F, Muratori M, Cavoretto D, Pepi M. Role of cine-fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol. 2000;85:58–64. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0002-9149(99)00607-4&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=11078238&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000084555000012&link_type=ISI) 220.220.Muratori M, Montorsi P, Teruzzi G, et al. Feasibility and diagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion by transthoracic and transesophageal echocardiography in suspected prosthetic valve dysfunction. Am J Cardiol. 2006;97:94–100. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.amjcard.2005.07.112&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16377291&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000234587200020&link_type=ISI) 221.221.Suh YJ, Lee S, Im DJ, et al. Added value of cardiac computed tomography for evaluation of mechanical aortic valve: emphasis on evaluation of pannus with surgical findings as standard reference. Int J Cardiol. 2016;214:454–60. 222.222.Symersky P, Budde RPJ, de Mol BAJM, Prokop M. Comparison of multidetector-row computed tomography to echocardiography and fluoroscopy for evaluation of patients with mechanical prosthetic valve obstruction. Am J Cardiol. 2009;104:1128–34. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.amjcard.2009.05.061&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19801036&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000270864600021&link_type=ISI) 223.223.Gürsoy OM, Karakoyun S, Kalçik M, Ozkan M. The incremental value of RT three-dimensional TEE in the evaluation of prosthetic mitral valve ring thrombosis complicated with thromboembolism. Echocardiography. 2013;30:E198–201. 224.224.Tong AT, Roudaut R, özkan M, et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol. 2004;43:77–84. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=43/1/77&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 225.225.Keuleers S, Herijgers P, Herregods MC, et al. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011;107:275–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.amjcard.2010.09.013&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21211605&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 226.226.Roudaut R, Lafitte S, Roudaut MF, et al. Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis. 2009;102:269–77. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.acvd.2009.01.007&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19427604&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 227.227.Karthikeyan G, Math RS, Mathew N, et al. Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation. 2009;120:1108–14. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=120/12/1108&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 228.228.Cáceres-Lóriga FM, Pérez-López H, Morlans-Hernandez K, et al. Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis. 2006;21:185–90. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1007/s11239-006-4969-y&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16622616&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000236954900010&link_type=ISI) 229.229.özkan M, Gündüz S, Biteker M, et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. J Am Coll Cardiol Img. 2013;6:206–16. 230.230.Nagy A, Dénes M, Lengyel M. Predictors of the outcome of thrombolytic therapy in prosthetic mitral valve thrombosis: a study of 62 events. J Heart Valve Dis. 2009;18:268–75. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19557981&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 231.231.özkan M, çakal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation. 2013;128:532–40. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=128/5/532&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 232.232.Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol. 1991;17:646–50. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=17/3/646&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 233.233.Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J. 2013;34:1557–66. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=34/21/1557&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 234.234.Huang G, Schaff HV, Sundt TM, Rahimtoola SH. Treatment of obstructive thrombosed prosthetic heart valve. J Am Coll Cardiol. 2013;62:1731–6. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=62/19/1731&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 235.235.Özkan M, Gündüz S, Gürsoy OM, et al. Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Am Heart J. 2015;170:409–18. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2015.04.025&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26299240&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 236.236.Laschinger JC, Wu C, Ibrahim NG, Shuren JE. Reduced leaflet motion in bioprosthetic aortic valves—the FDA perspective. N Engl J Med. 2015;373:1996–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMp1512264&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26437127&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 237.237.Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009;119:1034–48. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=FULL&journalCode=circulationaha&resid=119/7/1034&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 238.238.Koene BM, Soliman Hamad MA, Bouma W, et al. Impact of prosthesis-patient mismatch on early and late mortality after aortic valve replacement. J Cardiothorac Surg. 2013;8:96. 239.239.Maganti M, Rao V, Armstrong S, Feindel CM, Scully HE, David TE. Redo valvular surgery in elderly patients. Ann Thorac Surg. 2009;87:521–5. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2008.09.030&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19161771&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000262612600027&link_type=ISI) 240.240.Leontyev S, Borger MA, Davierwala P, et al. Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg. 2011;91:1120–6. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2010.12.053&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=21276956&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000288785800041&link_type=ISI) 241.241.Kaneko T, Vassileva CM, Englum B, et al. Contemporary outcomes of repeat aortic valve replacement: a benchmark for transcatheter valve-in-valve procedures. Ann Thorac Surg. 2015;100:1298–304; discussion 304. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2015.04.062&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26209480&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 242.242.Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J. Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol. 2012;109:257–62. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.amjcard.2011.08.038&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22000772&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 243.243.Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol. 2013;112:1439–44. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.amjcard.2013.06.014&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=23891426&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 244.244.Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg. 2015;47:725–32. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ejctsurg&resid=47/4/725&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 245.245.De Marchena E, Mesa J, Pomenti S, et al. Thrombus formation following transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2015;8:728–39. 246.246.Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015;8. 247.247.Webb JG, Wood DA, Ye J, et al. Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation. 2010;121:1848–57. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=121/16/1848&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 248.248.Phan K, Zhao DF, Wang N, Huo YR, Di EM, Yan TD. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. J Thorac Dis. 2016;8:E83–93. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=26904259&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 249.249.Administration USFaD. FDA expands use of CoreValue System for aortic “valve-in-valve replacement”. March 30, 2015. Available at: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440535.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440535.htm). Accessed January 20, 2017. 250.250.Akins CW, Bitondo JM, Hilgenberg AD, Vlahakes GJ, Madsen JC, MacGillivray TE. Early and late results of the surgical correction of cardiac prosthetic paravalvular leaks. J Heart Valve Dis. 2005;14:792–9; discussion 9–800. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=16359061&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000233497200018&link_type=ISI) 251.251.Miller DL, Morris JJ, Schaff HV, Mullany CJ, Nishimura RA, Orszulak TA. Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. J Heart Valve Dis. 1995;4:160–5. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8556176&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 252.252.Ruiz CE, Jelnin V, Kronzon I, et al. Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll Cardiol. 2011;58:2210–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=58/21/2210&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 253.253.Sorajja P, Cabalka AK, Hagler DJ, Rihal CS. Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ Cardiovasc Interv. 2011;4:314–21. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circcvint&resid=4/4/314&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 254.254.Sorajja P, Cabalka AK, Hagler DJ, Rihal CS. Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol. 2011;58:2218–24. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=58/21/2218&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 255.255.Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009;169:1290–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/archinternmed.2009.192&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19636030&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000268373000006&link_type=ISI) 256.256.Gordon SM, Serkey JM, Longworth DL, Lytle BW, Cosgrove DM III.. Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992–1997. Ann Thorac Surg. 2000;69:1388–92. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(00)01135-8&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=10881810&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000087605800022&link_type=ISI) 257.257.Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA. 2003;289:1933–40. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.289.15.1933&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=12697795&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000182253900025&link_type=ISI) 258.258.Jault F, Gandjbakhch I, Rama A, et al. Active native valve endocarditis: determinants of operative death and late mortality. Ann Thorac Surg. 1997;63:1737–41. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0003-4975(97)00117-3&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9205176&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1997XH23000041&link_type=ISI) 259.259.Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA. 2011;306:2239–47. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2011.1701&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22110106&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000297255500023&link_type=ISI) 260.260.Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest. 1992;101:37–41. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.101.1.37&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=1729106&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1992GX87100012&link_type=ISI) 261.261.Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.297.12.1354&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17392239&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000245212600022&link_type=ISI) 262.262.Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis. 2007;44:364–72. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cid&resid=44/3/364&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 263.263.Chirouze C, Cabell CH, Fowler VG Jr., et al. Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis. 2004;38:1323–7. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cid&resid=38/9/1323&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 264.264.Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis. 2001;32:50–62. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cid&resid=32/1/50&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 265.265.Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. 2007;28:196–203. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=28/2/196&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 266.266.Melgar GR, Nasser RM, Gordon SM, Lytle BW, Keys TF, Longworth DL. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore). 1997;76:94–103. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1097/00005792-199703000-00002&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=9100737&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 267.267.Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg. 2007;83:1295–302. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2006.09.093&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17383330&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000245178900011&link_type=ISI) 268.268.Wolff M, Witchitz S, Chastang C, Regnier B, Vachon F. Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest. 1995;108:688–94. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1378/chest.108.3.688&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=7656617&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1995RU34800021&link_type=ISI) 269.269.Anguera I, Miro JM, Vilacosta I, et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J. 2005;26:288–97. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=ehj&resid=26/3/288&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 270.270.Chan KL. Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. CMAJ. 2002;167:19–24. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cmaj&resid=167/1/19&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 271.271.Jault F, Gandjbakhch I, Chastre JC, et al. Prosthetic valve endocarditis with ring abscesses. Surgical management and long-term results. J Thorac Cardiovasc Surg. 1993;105:1106–13. [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8501938&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1993LG08700019&link_type=ISI) 272.272.Middlemost S, Wisenbaugh T, Meyerowitz C, et al. A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol. 1991;18:663–7. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=18/3/663&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 273.273.Wang K, Gobel F, Gleason DF, Edwards JE. Complete heart block complicating bacterial endocarditis. Circulation. 1972;46:939–47. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=46/5/939&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 274.274.Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J. 2007;154:923–8. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.ahj.2007.06.028&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=17967599&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000251146800020&link_type=ISI) 275.275.Klieverik LMA, Yacoub MH, Edwards S, et al. Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses. Ann Thorac Surg. 2009;88:1814–21. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2009.08.019&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=19932241&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000272029100014&link_type=ISI) 276.276.Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg. 2012;93:489–93. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/j.athoracsur.2011.10.063&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22206953&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000299540200029&link_type=ISI) 277.277.Athan E, Chu VH, Tattevin P, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA. 2012;307:1727–35. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1001/jama.2012.497&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22535857&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000303147500026&link_type=ISI) 278.278.Ho HH, Siu CW, Yiu KH, Tse HF, Chui WH, Chow WH. Prosthetic valve endocarditis in a multicenter registry of Chinese patients. Asian Cardiovasc Thorac Ann. 2010;18:430–4. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1177/0218492310379457&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=20947596&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 279.279.Rundström H, Kennergren C, Andersson R, Alestig K, Hogevik H. Pacemaker endocarditis during 18 years in Göteborg. Scand J Infect Dis. 2004;36:674–9. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1080/00365540410022611&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=15370655&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000224263400009&link_type=ISI) 280.280.Sohail MR, Uslan DZ, Khan AH, et al. Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc. 2008;83:46–53. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.4065/83.1.46&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=18174000&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000252114400007&link_type=ISI) 281.281.Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012;366:2466–73. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1056/NEJMoa1112843&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=22738096&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=000305747000006&link_type=ISI) 282.282.Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol. 1989;14:631–8. [FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=PDF&journalCode=accj&resid=14/3/631&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 283.283.Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005;112:69–75. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=112/1/69&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 284.284.Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg. 1995;110:1745–55. [CrossRef](http://circ.ahajournals.org/lookup/external-ref?access_num=10.1016/S0022-5223(95)70038-2&link_type=DOI) [PubMed](http://circ.ahajournals.org/lookup/external-ref?access_num=8523887&link_type=MED&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) [Web of Science](http://circ.ahajournals.org/lookup/external-ref?access_num=A1995TJ64300024&link_type=ISI) 285.285.Barsic B, Dickerman S, Krajinovic V, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis. 2013;56:209–17. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=cid&resid=56/2/209&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom) 286.286.García-Cabrera E, Fernández-Hidalgo N, Almirante B, et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127:2272–84. [Abstract/FREE Full Text](http://circ.ahajournals.org/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=127/23/2272&atom=%2Fcirculationaha%2F135%2F25%2Fe1159.atom)